SOHO 2021 | Personalization of care for MDS patients
Rami Komrokji
• 16 Aug 2021
Rami Komrokji, MD, of the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, explains how care can be personalized for patients with low- to high-risk myelodysplastic syndromes (MDS). Dr Komrokji talks on the importance of disease risk assessment to identify disease progression patterns, and speaks on how comorbidities like anemia and thrombocytopenia, age, the presence of mutations like IDH1/2, and symptomatic burden need to be taken into consideration to ensure the most appropriate treatments are allocated. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
